Trubogli- 0.3
One Method To Improve Drug Adherence


Composition : Voglibose 0.3mg

Form : Mouth Dissolving Tablets / Pack : 10 X 10s / Type : ALU ALU

Description : Voglibose should be co-administered in conjunction with diet treatment or diet plus oral hypoglycaemic drugs and dose titration must be recommended only if a response is not seen with 0.2 mg tid. The higher dose (0.3 mg three times daily) is effective in decreasing the reaction of VAT( visceral adipose tissue) to SATC (Subcutaneous Adipose Tissue) and glycaemic control was related to changes in VAT but not SATC.For IDDM patients, dose of 0.2 to 0.3 mg tid before meals is administered along with insulin administration - J Clin Diagn Res. 2013 Dec; 7(12): 3023–3027.

View more products with following salts

Trubogli- 0.2
One Method To Improve Drug Adherence


Composition : Voglibose 0.3mg

Form : Mouth Dissolving Tablets / Pack : 10 X 10s / Type : ALU ALU

Description : Voglibose should be co-administered in conjunction with diet treatment or diet plus oral hypoglycaemic drugs and dose titration must be recommended only if a response is not seen with 0.2 mg tid. The higher dose (0.3 mg three times daily) is effective in decreasing the reaction of VAT( visceral adipose tissue) to SATC (Subcutaneous Adipose Tissue) and glycaemic control was related to changes in VAT but not SATC.For IDDM patients, dose of 0.2 to 0.3 mg tid before meals is administered along with insulin administration - J Clin Diagn Res. 2013 Dec; 7(12): 3023–3027

View more products with following salts

Trubose Forte
One Method To Improve Drug Adherence


Composition : Nateglinide 60mg + Metformin 500mg + Voglibose 0.3mg

Form : Tablets / Pack : 10 X 10s / Type : ALU ALU

Description : In a study of 2741 patients on oral (OAD), there was an inverse relationship between OAD adherence and HbA1c; controlling for baseline HbA1c and therapy regimen, each 10% increase in oral diabetes medication adherence was associated with a 0.1% HbA1c decrease (P = 0.0004), suggesting that adherent patients are more likely to achieve glycemic control than the non-adherent ones - Indian Journal of Endocrinology & metabolism 2015, May June 19 (3) The estimated prevalence of 61.3 million in India is expected to rise to 101.2million (65% increase) by 2030 resulting in every fifth person with diabetes in the world will be an Indian – Ind.J. of Endocrinology & Metabolism-2013 Vol: 17 Iss: 4 P: 594-601.

View more products with following salts

Trubogli- DS
New Armamentarium for PPHG Management


Composition : Voglibose 0.3mg + Repaglinide 1mg

Form : Tablets / Pack : 1 x 10 / Type : A A

Description : A non-randomized, open labeled, non-comparative, single-centric study was conducted in total of 20 type 2 diabetes mellitus (T2DM) patients (9 men and 11 women, mean age 69.07 ± 3.495 years). Each patient was administered a fixed dose combination of voglibose 0.3mg & repaglinide 0.5/1mg three times a day, just before each meal for 30 days. Fasting blood glucose (FBG) & postprandial blood glucose (PPBG) was performed at baseline & at the end of study as assessment tools. At the end of study data was extractable only in 15 patients because 5 patient dropped out as they did not turn up for follow up at day 30.Postprandial blood glucose reduced significantly {-61.67mg/dl (95% confidence interval -76.79 to -46.54 p<0.0001)} from baseline at day 30. Also a significant reduction (p<0.0001) was found with FBG {-42.13mg/dl (Confidence interval -61.25 to -23.02 P value <0.0001)} at end of day 30. There were no adverse events reported including hypoglycemia. Voglibose and Repaglinide combination was effective and safe for the management of PPHG in T2DM patients- Global Journal of Obesity, Diabetes and Metabolic Syndrome- 2017

View more products with following salts

Trubogli- XL
New Armamentarium for PPHG Management


Composition : Voglibose 0.3mg + Repaglinide 0.5mg

Form : Tablets / Pack : 1 x 10"s / Type : A A

Description : A non-randomized, open labeled, non-comparative, single-centric study was conducted in total of 20 type 2 diabetes mellitus (T2DM) patients (9 men and 11 women, mean age 69.07 ± 3.495 years). Each patient was administered a fixed dose combination of voglibose 0.3mg & repaglinide 0.5/1mg three times a day, just before each meal for 30 days. Fasting blood glucose (FBG) & postprandial blood glucose (PPBG) was performed at baseline & at the end of study as assessment tools. At the end of study data was extractable only in 15 patients because 5 patient dropped out as they did not turn up for follow up at day 30.Postprandial blood glucose reduced significantly {-61.67mg/dl (95% confidence interval -76.79 to -46.54 p<0.0001)} from baseline at day 30. Also a significant reduction (p<0.0001) was found with FBG {-42.13mg/dl (Confidence interval -61.25 to -23.02 P value <0.0001)} at end of day 30. There were no adverse events reported including hypoglycemia. Voglibose and Repaglinide combination was effective and safe for the management of PPHG in T2DM patients- Global Journal of Obesity, Diabetes and Metabolic Syndrome- 2017

View more products with following salts

Trubogli Plus
New Armamentarium for PPHG Management


Composition : Voglibose 0.2mg + Repaglinide 0.5mg

Form : Tablets / Pack : 1 x 10"s / Type : A A

Description : A non-randomized, open labeled, non-comparative, single-centric study was conducted in total of 20 type 2 diabetes mellitus (T2DM) patients (9 men and 11 women, mean age 69.07 ± 3.495 years). Each patient was administered a fixed dose combination of voglibose 0.3mg & repaglinide 0.5/1mg three times a day, just before each meal for 30 days. Fasting blood glucose (FBG) & postprandial blood glucose (PPBG) was performed at baseline & at the end of study as assessment tools. At the end of study data was extractable only in 15 patients because 5 patient dropped out as they did not turn up for follow up at day 30.Postprandial blood glucose reduced significantly {-61.67mg/dl (95% confidence interval -76.79 to -46.54 p<0.0001)} from baseline at day 30. Also a significant reduction (p<0.0001) was found with FBG {-42.13mg/dl (Confidence interval -61.25 to -23.02 P value <0.0001)} at end of day 30. There were no adverse events reported including hypoglycemia. Voglibose and Repaglinide combination was effective and safe for the management of PPHG in T2DM patients- Global Journal of Obesity, Diabetes and Metabolic Syndrome- 2017

View more products with following salts

Trubogli Forte
New Armamentarium for PPHG Management


Composition : Voglibose 0.2mg + Repaglinide 1mg

Form : Tablets / Pack : 1 x 10"s / Type : A A

Description : A non-randomized, open labeled, non-comparative, single-centric study was conducted in total of 20 type 2 diabetes mellitus (T2DM) patients (9 men and 11 women, mean age 69.07 ± 3.495 years). Each patient was administered a fixed dose combination of voglibose 0.3mg & repaglinide 0.5/1mg three times a day, just before each meal for 30 days. Fasting blood glucose (FBG) & postprandial blood glucose (PPBG) was performed at baseline & at the end of study as assessment tools. At the end of study data was extractable only in 15 patients because 5 patient dropped out as they did not turn up for follow up at day 30.Postprandial blood glucose reduced significantly {-61.67mg/dl (95% confidence interval -76.79 to -46.54 p<0.0001)} from baseline at day 30. Also a significant reduction (p<0.0001) was found with FBG {-42.13mg/dl (Confidence interval -61.25 to -23.02 P value <0.0001)} at end of day 30. There were no adverse events reported including hypoglycemia. Voglibose and Repaglinide combination was effective and safe for the management of PPHG in T2DM patients- Global Journal of Obesity, Diabetes and Metabolic Syndrome- 2017

View more products with following salts

Grilp – 10
An Adjunct To Diet And Exercise


Composition : Dapagliflozin 10mg

Form : Tablets / Pack : 1 X 10's / Type : AA

Description : Dapagliflozin is in a class of drug called SGLT2 inhibitors that works by targeting and helping to stop sodium-glucose transport proteins from allowing glucose that has been filtered out of the blood by the kidneys to be reabsorbed back into the blood. The SGLT2 proteins are responsible for 90% of the glucose that is reabsorbed into the blood. By inhibiting the SGLT2 proteins. Dapagliflozin allows a significant amount of glucose in the blood to be removed by the kidneys and excreted in the urine. SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of heart failure - The Lancet, Vol.- 393, Iss.-10166, p31-39.

View more products with following salts

Tinage- M1000
More Diabetic Friendly Combination


Composition : Teneligliptin 20mg + Metformin 1000mg

Form : Tablets / Pack : 1 X 10s / Type : AA

Description : Since DPP-4 inhibitors and metformin improve glycemic control via different albeit potentially complementary mechanisms. Combination therapy with these two agents should provide effective and potentially additive glycemic control. Studies using combination therapy of DPP-4 inhibitors and metformin (as one pill) showed favorable results in glycemic control because of favorable pharmacokinetic characteristics and complementary pharmacodynamic effects, which include enhanced incretin effect, suppressed hepatic glucose production, and improved peripheral insulin sensitivity. Moreover, in general, the combination of this drug into a single tablet improves patients’ compliance and often results in a lower cost of treatment. Indeed several fixed-dose combinations have been developed and/or commercialized - Diabetes Metab Syndr Obes. 2013; 6: 187–195.

View more products with following salts

Tinage-M500
More Diabetic Friendly Combination


Composition : Teneligliptin 20mg + Metformin 500mg

Form : Tablets / Pack : 1 X 10s / Type : AA

Description : Since DPP-4 inhibitors and metformin improve glycemic control via different albeit potentially complementary mechanisms. Combination therapy with these two agents should provide effective and potentially additive glycemic control. Studies using combination therapy of DPP-4 inhibitors and metformin (as one pill) showed favorable results in glycemic control because of favorable pharmacokinetic characteristics and complementary pharmacodynamic effects, which include enhanced incretin effect, suppressed hepatic glucose production, and improved peripheral insulin sensitivity. Moreover, in general, the combination of this drug into a single tablet improves patients’ compliance and often results in a lower cost of treatment. Indeed several fixed-dose combinations have been developed and/or commercialized - Diabetes Metab Syndr Obes. 2013; 6: 187–195.

View more products with following salts